Celgene dans l'actualité
Découverte de médicaments innovants
Tamtam a trouvé 20 articles récents sur Celgene.
- ANTITRUST—D.N.J.: Revlimid buyers’ pay-for-delay antitrust claims survive drugmakers’ motion to dismiss
- Bristol-Myers, Natco And More Can't Ditch Cancer Drug MDL
- Celgene, Teva, others must face US antitrust claims over Revlimid, judge rules
- Celgene Fails to Fend Off Antitrust Claims in Pay-for-Delay Suit
- Celgene, Teva, others must face US antitrust claims over Revlimid, judge rules
- Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene
- What Does Bristol Myers Squibb (BMY) Risk From The Revived $6.7 Billion Lawsuit?
- Bristol Myers Squibb Faces Revival of USD 6.7 Billion Celgene Shareholders' Lawsuit
- Appeals court revived a $6.7 billion lawsuit against Bristol Myers Squibb over delayed drug approvals
- US appeals court revives $6.7 billion lawsuit against Bristol Myers Squibb
- Appeals court revives $6.7B lawsuit against Bristol Myers Squibb
- Health Plans Ask 2nd Circ. To Revive Celgene Cancer Drug Row
- Health Plans Ask 2nd Circ. To Revive Celgene Cancer Drug Row
- Celgene Number of Employees 2026 | Employee Count & Headcount Data
- Health Plans Ask 2nd Circ. To Revive Celgene Cancer Drug Row
- Bristol Myers Squibb stock trades steady as oncology revenue and Celgene legacy shape valuation
- Scleroderma Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Bayer, Novartis, GSK, Boehringer Ingelheim, Celgene Corp., Johnson & Johnson
- Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
- FDA decision: Iberdomide by Celgene (in 2026)
- How Bristol Is Building On Its $74 Billion Celgene Buyout With New 'Molecular Glue'
Articles collectés par Tamtam et retenus lorsqu'ils portent sur l'entreprise, des plus récents aux plus anciens. Chacun renvoie à sa source.
Vous vendez à des entreprises comme Celgene ?
Tamtam trouve les entreprises qui correspondent à votre client idéal, analyse chaque compte et vous dit qui contacter, et quand.
Trouver des entreprises similaires